RxDoctor Payments Data

Andrew Grubic, DO

Surgery · Wexford, PANPI 1083031561

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Dilon Technologies, Inc. at 24.6% of the total. Reporting peaked in 2023 at $598 and has fallen 65.0% since, to $209 in 2025. That places this record below the midpoint for surgery clinicians in PA, where the typical reported total is $1,143.

$1,458in general payments, 2019–2025

Across 22 payments — averaging $66.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dilon Technologies, Inc.$359
  • Aroa Biosurgery Incorporated$241
  • Pinnacle Biologics, Inc$194
  • Innovation Technologies Inc$140
  • Johnson & Johnson$136
  • Teleflex LLC$108
  • plus $280 from 4 others

What the payments were for

  • Food & beverage$1,458100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,458 in reported general payments places this provider in the 50th percentile of 1,424 surgery providers in Pennsylvania.

See all surgery providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$57,649
Medicare patients
193
Services billed
426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sucralfate92$1,781
Colestipol Hcl19$1,477
Scopolamine16$1,238
Pantoprazole Sodium192$1,122
Ondansetron OdtOndansetron39$556
Prochlorperazine Maleate19$518
Omeprazole11$248
Famotidine18$237
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl16$196
Promethazine Hcl18$173

Paid to pharmacies, not to this prescriber.

Other surgery in Wexford

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →